Growth Hormone Axis · Growth Hormone Axis peptide (research)
CJC-1295 (No DAC)
- Drug class
- Growth Hormone Axis peptide (research)
- Status
- Compounded (503A)
- Also known as
- cjc1295 no dac, mod grf 1-29, modified grf, cjc no dac
- Reviewed
- 2026-06-01 · Dr. Ana Lisa Carr, MD
What CJC-1295 (No DAC) is studied for
- Pulsatile GH (research)
- Recovery (research)
- Sleep architecture (research)
Mechanism of action
CJC-1295 (No DAC) is being studied in the growth hormone axis category. Short-acting GHRH analog — clean pulsatile GH release. Mechanism of action varies by study model; refer to the kindr clinical library for a deeper writeup.
Frequently asked questions
What is CJC-1295 (No DAC)?
CJC-1295 (No DAC) is a growth hormone axis peptide. Short-acting GHRH analog — clean pulsatile GH release.
What is CJC-1295 (No DAC) studied for?
Published research has examined CJC-1295 (No DAC) for pulsatile gh, recovery, sleep architecture. Human clinical evidence varies by indication.
Is CJC-1295 (No DAC) FDA-approved?
No. CJC-1295 (No DAC) is not FDA-approved for the indications listed. It is available compounded by 503A pharmacies under clinician supervision, or for international research use only on this catalog.
How is CJC-1295 (No DAC) used in research?
Protocols vary by study. CJC-1295 (No DAC) is typically administered subcutaneously in research settings. No validated human therapeutic dose exists outside FDA-approved indications.
What are the known risks?
Long-term human safety data for CJC-1295 (No DAC) is limited. Theoretical risks vary by mechanism. Any human use should be supervised by a licensed clinician.